Treatment approach in chronic hepatitis C infection

Objective & Hypothesis:Purpose: We aimed to evaluate retrospectively the results of treatment of patients with chronic hepatitis C in our clinic.Material and Methods: We evaluated the treatment results of 109 patients who treated with the diagnosis of chronic hepatitis C between the years of 2003-2015 in our clinic.Results: The 52.3% of the patients were male, the mean age was 52.3, mean ALT value 58.3 IU/ml and average HCV-RNA levels was 3,7x106 IU/ml.

📊

Key Findings & Data:Previous treatment history in 47 patients (43%) was available.

💡

Conclusion & Impact:There is a need for new antiviral drugs that used in the world for the patients infected with genotype 1 who had unsuccessful treatment.

🔬Design:Research Article

📍Scope:2003-2015 Verileri

⚙️Variables:Anahtar Kelimeler Kronik hepatit C · genotip 1 · kalıcı virolojik yanıt

Abstract

Purpose: We aimed to evaluate retrospectively the results of treatment of patients with chronic hepatitis C in our clinic.Material and Methods: We evaluated the treatment results of 109 patients who treated with the diagnosis of chronic hepatitis C between the years of 2003-2015 in our clinic.Results: The 52.3% of the patients were male, the mean age was 52.3, mean ALT value 58.3 IU/ml and average HCV-RNA levels was 3,7x106 IU/ml. Previous treatment history in 47 patients (43%) was available. Eigthy-one patients (74.3%) received treatment of pegylated interferon and ribavirin and 28 patients(25.7%) received combination of pegylated interferon, ribavirin and telaprevir. Early virologic response were obtained in 99(90.8%) of 109 patients. Sustained virologic response was more higher in patients who achieved early virologic response. Sustained viralogic response in group of PegIFN/R was %74.1 and in group of PegIFN/R/T was 76.9%. At least one of complaints as rash, itching, taste disorder and anorectal pain were observed in PegIFN/R/T group. All patients had anemia as the most common hematologic side-effect. Depressive symptoms was observed in 19% of patients.Conclusion: With available treatment options in our country, patients who can not be achieved to SVR rates are available. There is a need for new antiviral drugs that used in the world for the patients infected with genotype 1 who had unsuccessful treatment.

Özet

Amaç: Kliniğimizde kronik hepatit C nedeni ile izlenen hastaların tedavi sonuçlarının retrospektif olarak değerlendirilmesi amaçlanmıştır.Gereç ve Yöntem: Kliniğimizde 2003-2015 yılları arasında kronik hepatit C tanısı ile tedavi gören 109 hastanın tedavi sonuçları değerlendirildi. Bulgular: Hastaların %52.3’ü erkek, ortalama yaş 52.3, ortalama ALT değeri 58.3 IU/ml ve ortalama HCV-RNA düzeyi 3,7x106 IU/ml idi. Hastaların 47’sinde (%43) önceden tedavi öyküsü mevcuttu. Seksen bir hasta (%74,3) pegileinterferon ve ribavirin (PegIFN/R), 28 (%25.7) hasta ise pegileinterferon, ribavirin ve telaprevir (PegIFN/R/T) kombinasyonu aldı. Erken virolojik yanıt 109 hastanın 99’unda (%90.8) alındı. Erken virolojik yanıt alınan hastalarda erken virolojik yanıt alınmayan hastalara göre kalıcı viral yanıt anlamlı oranda yüksekti. Kalıcı viral yanıt PegIFN/R alanlarda %74.1 ve PegIFN/R/T alanlarda ise %76.9 idi. PegIFN/R/T alan tüm hastalarda döküntü, kaşıntı, tat bozukluğu ve anorektal ağrı yakınmalarından en az biri görüldü. Tüm hastalarda anemi en sık görülen hematolojik yan etkiydi. Hastaların %19’unda depresif yakınmalar izlendi.Sonuç: Ülkemizdeki tedavi seçenekleri ile kalıcı viral yanıt elde edilemeyen hastalar mevcuttur. Tedavi edemediğimiz genotip 1 ile enfekte hastalar için dünyada kullanılmakta olan ve başarılı sonuçlar veren yeni antivirallere ihtiyaç duyulmaktadır.

Keywords

Anahtar Kelimeler Kronik hepatit C genotip 1 kalıcı virolojik yanıt

🔖

Cite This Article

KÖMÜR, S., KUŞÇU, F., ULU, A., İNAL, A., KURTARAN, B., TAŞOVA, Y., AKSU, H. (2016). Treatment approach in chronic hepatitis C infection. Cukurova Medical Journal, Cilt: 41 - Sayı: 2, 342–346. https://ajindex.com/articles/56786

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (11)

Lavanchy D. Evolving epidemiology of hepatitis C virüs. Clin Microbiol Infect. 2011;17:107-15. European Association fort he Study of the Liver. EASL recommendations on treatment of hepatitis C. J Hepatol. 2015;63:199-236.
Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk S et al. Retreatment of chronic hepatitis c infection with telaprevir: preliminary results in turkey. Balkan Med J. 2015;32:266-72.
Ghany MC, Strader DB, Thomas DL, Seef LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2009;49:1335-74.
Zeuzem S, Feinman SV, Rasenack J, Heathcoke EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med, 2000;343:1666-72.
Lindsay KL, Trepo C, Heintges T, Schiffman MC, Gordon SC, Hoefs JC et al. A randomized, double- blind trial pegylated interferon alfa-2a to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med, 2004;140:346-55.
Fried MW, Shiffman ML, Reddy R, Smith C, Marines G, Goncales FL et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment for chronic hepatitis C. a randomised trial. Lancet. 2001;358:958- 65. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhaces sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-9.
Akıncı E, Kayaaslan BÜ, Başbuğ A, Eren SS, Öngürü P, Bodur H. Genotip 1b kronik hepatit c hastalarında kalıcı virolojik yanıtın değerlendirilmesi. Viral Hepatit Dergisi. 2013;19:80-4. Ersöz G. Hepatit C tedavisi. Turkiye Klinikleri J Gastroenterohepatol-Special Topics. 2010;3:96-10.
Elefsiniotis IS, Pavlidis C, Ketikoglou I, Koutsounas S, Scarmeas N, Pantazis KD et al. Patient’s age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Eur J Int Med. 2008;19:266-270.
Özden K, Özkurt Z, Erol S, Parlak